Libya Pharmaceutical Market 2024-2030

KEY FINDINGS

• The main challenges facing the pharmaceutical industry in Libya is the lack of medicines and medical supplies.
• Improving logistics and supply chain management is a major factor in ensuring the success and sustainability of Libya's healthcare sector. 
• By streamlining logistics and supply chain management, the healthcare sector in Libya can be strengthened to effectively meet the needs of Libyan citizens.
• The growth of the market is being driven by a number of factors, an increasing population, rising disposable incomes, an aging population, growing prevalence of chronic diseases.
• The government is also playing a role in the growth of the market by investing in healthcare infrastructure and implementing policies to improve access to medicines.
• Libya imports most of its pharmaceuticals from India, Germany and Turkey .
• Libya spent 3.6% of its GDP on health, and the per capita health expenditure in PPP-adjusted USD was about 958 USD.
• Over the course of 2010, the majority of health expenditure (69.9%) came from the government while the rest (30%) came from the private sector.
• Libya has a large number of health professionals but they are poorly distributed, resulting in severe human resource shortages in many health facilities.
• A total of 397 (27%) of the PHC facilities and hospitals surveyed reported offering pharmaceutical services or having a main storage area for pharmaceuticals, with 80% of services available in PHC facilities and 20% in hospitals.  
• Additionally, 52 functional medical supply stores were available to house and distribute medical supplies to individual health facilities (WHO, MoH of Libya & EU, 2017) 

LIBYA PHARMACEUTICAL MARKET OVERVIEW

The private sector powerfully contributes to providing better-quality health services. It covers services ranging from hospitals, clinics, and laboratories to medicines, vaccines, and other services such as ambulances and insurance.The Libyan healthcare sector has come a long way and still has a lot of room for growth and improvement. The role of private sector companies, such as AlSahl Group Holding, in providing quality healthcare services and products is commendable.

Collaboration between international organizations and the Libyan government is also crucial in addressing the sector's challenges, upgrading infrastructure, improving access to health services, and managing public health emergencies. The Libyan pharmaceutical market is dominated by generics, which account for over 80% of the market. However, there is a growing demand for branded medicines, particularly in the areas of oncology, diabetes, and cardiovascular diseases.

The main distribution channels for pharmaceuticals in Libya are pharmacies, hospitals, and public health facilities. However, there is a growing trend of online pharmacies and drug delivery services. The Libyan pharmaceutical market is highly fragmented, with a large number of small and medium-sized enterprises (SMEs) operating in the market. However, there is a trend of consolidation, with a number of larger companies acquiring smaller players.

Libya Import data, Pharmaceutical import shipments in Libya stood at 2.1K, imported by 198 Libya Importers from 110 Suppliers.The top three importers of Pharmaceuticals are India, with 501,461 shipments, followed by the United States, with 226,324 shipments, and Pakistan, with 204,667 shipments.

INTRODUCTION

The pharmaceutical industry in Libya has evolved over time, primarily due to the Libyan government's investment in the health system and pharmaceutical industry, which has resulted in the establishment of public pharmaceutical companies and the construction of new factories and hospitals.The efforts to improve the industry continue to present times, both in the public and private sectors, to ensure that Libyans have access to the necessary medical supplies and medicines. The private sector is heavily and constantly contributing to the ongoing shift of Libya healthcare.

International humanitarian organizations, such as theUnited Nations Development Programme(UNDP) andGIZ, are constantly creating projects to support Libya healthcare and their collaboration with the Libyan government is always essential.The shortage of medical supplies (disposable medical products and essential pharmaceuticals) and the inadequate medical supply system are considered significant problems in the medical supplies and technology aspect in Libya.

Health care facilities do not receive additional funding for their pharmaceutical, infrastructure and construction needs. Although municipalities are responsible for coordinating and providing some health care services in their areas, they also do not receive any funds and are not able to collect money from local taxes or other revenue sources.The majority of pharmaceutical items have historically been imported into Libya due to the country's poor capacity for pharmaceutical manufacturing.Conflicts and political unrest have hampered domestic output.

Libya is significantly dependent on imports for pharmaceutical goods, especially finished pharmaceuticals and active pharmaceutical ingredients (APIs), due to the country's poor capability for domestic manufacturing.For the population's health care demands to be met, these imports are necessary. It has been difficult for Libyans to obtain necessary medications, especially during times of unrest and instability. Access to cheap medical services and medications for the general public has been worked on.

LIBYA PHARMACEUTICAL MARKET SIZE AND FORECAST

The Libya pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

TRENDS IN LIBYA PHARMACEUTICAL MARKET

1. Authorities Seize Counterfeit Medicines

• In October 2023, authorities in Libya seized 12 types of counterfeit medicines that were being sold in the local market.
• This highlights the ongoing challenge of counterfeit medicines in Libya, which poses a serious threat to public health.

2. Government Invests in Pharmaceutical Manufacturing

• The Libyan government has announced plans to invest in the construction of new pharmaceutical manufacturing plants.
• This investment is aimed at reducing the country's reliance on imported medicines and boosting local production.

3. 2D Barcodes Mandated for Pharmaceutical Products

• In July 2023, the Ministry of Economy and Commerce in Libya issued a decision requiring the application of a GS1 DataMatrix 2D barcode on all pharmaceutical products and medical equipment supplied to the Libyan market.
• This is expected to improve traceability and combat counterfeit drugs.

4. AlSahl Group Invests in Healthcare Sector

• AlSahl Group Holding, a major Libyan conglomerate, has announced plans to invest in the healthcare sector, including the import of essential medicines and pharmaceuticals.
• This investment is expected to improve access to quality medical products for the Libyan public.
  

LIBYA PHARMACEUTICAL MARKETNEW PRODUCT LAUNCH

Novartis: Entresto (Sacubitril/Valsartan):Treatment of chronic heart failure with reduced ejection fraction. First-in-class angiotensin receptor-neprilysin inhibitor (ARNI) to be launched in Libya, offering a more effective treatment option for heart failure patients.

MSD: Keytruda (Pembrolizumab):Treatment of various types of cancer, including melanoma, lung cancer, and head and neck cancer. First anti-PD-1 immunotherapy to be launched in Libya, providing new hope for cancer patients.

Sanofi: Toujeo (Insulin glargine U300):Treatment of diabetes mellitu. First concentrated insulin glargine formulation to be launched in Libya, offering greater convenience and flexibility for patients.

Boehringer Ingelheim: Jardiance (Empagliflozin):Treatment of type 2 diabetes. First SGLT2 inhibitor to be launched in Libya, offering a new class of medication for diabetes management.

Gilead Sciences: Biktarvy (Bictegravir/Emtricitabine/Tenofovir Alafenamide):Treatment of HIV-1 infection. First single-tablet regimen for HIV treatment to be launched in Libya, offering a more convenient and effective treatment option for patients.

LIBYA PHARMACEUTICAL MARKET SEGMENTATION

By Drug Type

• Branded Drug
• Generic Drug
• Over-the-Counter (OTC) Drugs
• Prescription drugs
• Biopharmaceuticals

By Therapy Area

• Cardiovascular diseases
• Pain
• Diabetes
• Cancer
• Respiratory diseases

By Distribution Channel

• Public sector
• Pharmacies
• Hospitals
• Public health facilities
• Online pharmacies

ByMolecule Type

• Small-molecule drugs
• Large-molecule drugs

LIBYA PHARMACEUTICAL MARKETCOMPANY PROFILE

• Johnson and Johnson Services Inc
• Bayer AG
• Novartis AG
• Sanofi
• Pfizer
• GlaxoSmithKline Plc 
• Boehringer Ingelheim International GmbH
• Reckitt Benckiser Group Plc
• Takeda Pharmaceuticals
• AlSahl Group Holding

THIS REPORT WILL ANSWER THE FOLLOWING QUESTIONS

1. What is the current size of the Libyan pharmaceutical market?
2. What is the expected growth rate of the market over the next five years?
3. What are the key factors driving the growth of the market?
4. What are the major challenges facing the market?
5. How is the market segmented by product type (generics, branded, OTC, etc.)?
6. How is the market segmented by therapy area (cardiovascular, oncology, diabetes, etc.)?
7. How is the market segmented by distribution channel (pharmacies, hospitals, online, etc.)?
8. What are the key trends in each segment of the market?
9. What are the key regulations governing the pharmaceutical market in Libya?
10. What are the challenges and opportunities presented by the regulatory environment?
11. How are the regulations impacting the market's growth and development?
12. Who are the major players in the Libyan pharmaceutical market?
13. What are their market shares and competitive strategies?
14. What are the key trends in mergers and acquisitions activity in the market?
15. How are international companies entering the Libyan market?
16. What are the key trends that will shape the future of the Libyan pharmaceutical market?
17. What are the opportunities and challenges for pharmaceutical companies operating in Libya?
18. How is the market expected to evolve in the next five to ten years?
19. What are the specific needs of patients in Libya in terms of pharmaceutical access and affordability?
20. What role can the government play in improving access to essential medicines in Libya?